Myocardial Infarction Market
- 2026 年市場規模
- USD 2.42 Bn
- 2033 年預估規模
- USD 3.61 Bn
- 年複合成長率 CAGR
- 5.9%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Myocardial Infarction Market, By Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, Thrombolytics), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Myocardial Infarction is also known as heart attack. Heart attack occurs when one of the coronary arteries of the heart becomes suddenly blocked or has extremely slow blood flow.
The formation of a blood clot is the most common cause of a sudden blockage in a coronary artery (thrombus). The blood clot usually forms inside a coronary artery that has already been narrowed by atherosclerosis, a condition in which fatty deposits (plaques) accumulate along the inside wall of the artery.
Chest discomfort, pain, or discomfort in the upper body, shortness of breath, sweating, indigestion, dizziness, or extreme weakness, and anxiety are all symptoms of a heart attack. ECG and blood tests are conducted to diagnose heart attack. Drugs such as vasodilators, aspirin, and beta blockers are used to treat heart attack.
Market Dynamics
Market players and non-profit organizations are focused on initiatives related to heart attack, which is expected to contribute to the growth of the global myocardial infarction market over the forecast period. For instance, on May 17, 2021, the American College of Cardiology (ACC), a non-profit medical association, announce d that its’ Global Heart Attack Treatment Initiative (GHATI) had measurable positive effects on heart attack care delivery in low-and middle-income countries. The initiative was launched in 2019 with the goal of improving heart attack outcomes in low and middle-income countries by encouraging adherence to medical therapy based on guidelines.
Market players are focusing on product launches which is expected to strengthen their position in the global myocardial infarction market. For instance, on June 1, 2020, AstraZeneca plc., a leading international biopharmaceutical company, announced that its' drug Brilinta (ticagrelor) have been approved by the U.S. Food and Drug Administration (FDA), to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.
Market players and government organizations are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, which is expected to drive the growth of the global myocardial infarction market. For instance, on October 4, 2020, Amgen Inc., a multinational biotechnology company, announced a new collaboration with two National Health Service (NHS) organizations in the UK: the North West Coast Innovation Agency and Imperial College Health Partners. This collaboration will aid in the fight against the silent killer of high cholesterol along the North West Coast of England, an area plagued by heart attacks, strokes, and premature death by cardiovascular diseases.
Key features of the study
• This report provides an in-depth analysis of global myocardial infarction market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global myocardial infarction market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global myocardial infarction market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global myocardial infarction market.
Market Segmentation
• By Drug Class (Revenue, USD Bn, 2021-2033)
o Antiplatelet Agents
o Glycoprotein IIb/IIIa Inhibitors
o Antithrombotic Agents
o Beta-adrenergic Blockers
o Vasodilators
o Angiotensin-converting Enzyme (ACE) Inhibitors
o Angiotensin-receptor Blockers
o Analgesics
o Thrombolytics
• By Route of Administration (Revenue, USD Bn, 2021-2033)
o Oral
o Injectable
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Bristol-Myers Squibb Co.
o Bayer AG
o Johnson & Johnson Services Inc.
o Sanofi S.A.
o Novartis International AG
o AstraZeneca plc.
o Daiichi Sankyo Co Ltd
o Boehringer Ingelheim International GmbH
o Pfizer Inc.
o Merck KGaA
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Class
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Myocardial Infarction Market, By Drug Class, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Antiplatelet Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Glycoprotein IIb/IIIa Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Antithrombotic Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Beta-adrenergic Blockers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Vasodilators
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Angiotensin-converting Enzyme (ACE) Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Angiotensin-receptor Blockers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Analgesics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Thrombolytics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
5. Global Myocardial Infarction Market, By Route of Administration, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Injectable
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. Global Myocardial Infarction Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
7. Global Myocardial Infarction Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Bristol-Myers Squibb Co.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bayer AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Johnson & Johnson Services Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Sanofi S.A.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis International AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AstraZeneca plc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Daiichi Sankyo Co Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Boehringer Ingelheim International GmbH
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Merck KGaA
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們